Research programme: induced pluripotent stem cell-derived therapeutics - Foundation for Biomedical Research and Innovation /RIKEN/Santen

Drug Profile

Research programme: induced pluripotent stem cell-derived therapeutics - Foundation for Biomedical Research and Innovation /RIKEN/Santen

Alternative Names: iPS therapeutics - Santen Pharmaceutical

Latest Information Update: 14 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Foundation Fighting Blindness Clinical Research Institute; RIKEN; Santen Pharmaceutical
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Retinitis pigmentosa

Most Recent Events

  • 06 Nov 2016 Santen Pharmaceutical, RIKEN, and the Foundation for Biomedical Research and Innovation agree to co-develop induced pluripotent stem cell-derived therapeutics in Japan for Retinitis pigmentosa and Age-related macular degeneration
  • 06 Oct 2016 Early research in Retinitis pigmentosa and Age-related macular degeneration in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top